NOVAVAX INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NOVAVAX INC (NVAX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.09M, a 12.21% decline year-over-year.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.72M, a 24.90% decline year-over-year.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $7.97M, a 23.75% decline year-over-year.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.55M, a 29.05% decline year-over-year.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $36.02M, a 25.21% decline from fiscal 2024.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $48.15M, a 43.91% decline from fiscal 2023.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $85.85M, a 34.95% decline from fiscal 2022.
- NOVAVAX INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $131.97M, a 28.13% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.09M 10-Q · filed 2026-08-06 | $15.81M 10-Q · filed 2026-08-06 | $23.78M derived: sum of 3 quarters · filed 2026-08-06 | $32.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $7.72M 10-Q · filed 2026-05-06 | $15.69M derived: sum of 2 quarters · filed 2026-05-06 | $24.24M derived: sum of 3 quarters · filed 2026-05-06 | $33.45M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.52M derived: sum of 2 quarters · filed 2026-02-26 | $25.73M derived: sum of 3 quarters · filed 2026-08-06 | $36.02M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $8.55M 10-Q · filed 2025-11-06 | $17.76M derived: sum of 2 quarters · filed 2026-08-06 | $28.05M 10-Q · filed 2025-11-06 | $38.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $9.21M 10-Q · filed 2026-08-06 | $19.50M 10-Q · filed 2026-08-06 | $29.95M derived: sum of 3 quarters · filed 2026-08-06 | $42.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $10.29M 10-Q · filed 2026-05-06 | $20.73M derived: sum of 2 quarters · filed 2026-05-06 | $32.78M derived: sum of 3 quarters · filed 2026-05-06 | $46.88M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.50M derived: sum of 2 quarters · filed 2026-02-26 | $36.60M derived: sum of 3 quarters · filed 2026-02-26 | $48.15M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $12.05M 10-Q · filed 2025-11-06 | $26.15M derived: sum of 2 quarters · filed 2025-11-06 | $37.70M 10-Q · filed 2025-11-06 | $53.36M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $14.10M 10-Q · filed 2025-08-06 | $25.66M 10-Q · filed 2025-08-06 | $41.31M derived: sum of 3 quarters · filed 2026-02-26 | $62.57M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $11.56M 10-Q · filed 2025-05-08 | $27.21M derived: sum of 2 quarters · filed 2026-02-26 | $48.47M derived: sum of 3 quarters · filed 2026-02-26 | $68.76M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $15.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.91M derived: sum of 2 quarters · filed 2026-02-26 | $57.20M derived: sum of 3 quarters · filed 2026-02-26 | $85.85M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $21.25M 10-Q · filed 2024-11-12 | $41.55M derived: sum of 2 quarters · filed 2024-11-12 | $70.19M 10-Q · filed 2024-11-12 | $97.79M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $20.29M 10-Q · filed 2024-08-08 | $48.94M 10-Q · filed 2024-08-08 | $76.54M derived: sum of 3 quarters · filed 2025-02-27 | $109.92M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $28.65M 10-Q · filed 2024-05-10 | $56.25M derived: sum of 2 quarters · filed 2025-02-27 | $89.63M derived: sum of 3 quarters · filed 2025-02-27 | $127.68M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $27.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $60.99M derived: sum of 2 quarters · filed 2025-02-27 | $99.03M derived: sum of 3 quarters · filed 2025-02-27 | $131.97M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $33.39M 10-Q · filed 2023-11-09 | $71.43M derived: sum of 2 quarters · filed 2023-11-09 | $104.37M 10-Q · filed 2023-11-09 | $136.54M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $38.05M 10-Q · filed 2023-08-08 | $70.98M 10-Q · filed 2023-08-08 | $103.15M derived: sum of 3 quarters · filed 2024-02-28 | $148.42M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $32.93M 10-Q · filed 2023-05-09 | $65.10M derived: sum of 2 quarters · filed 2024-02-28 | $110.38M derived: sum of 3 quarters · filed 2024-02-28 | $163.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $32.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $77.44M derived: sum of 2 quarters · filed 2024-02-28 | $130.57M derived: sum of 3 quarters · filed 2024-02-28 | $183.63M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $45.27M 10-Q · filed 2022-11-09 | $98.40M derived: sum of 2 quarters · filed 2022-11-09 | $151.46M 10-Q · filed 2022-11-09 | $201.89M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $53.12M 10-Q · filed 2022-08-09 | $106.18M 10-Q · filed 2022-08-09 | $156.62M derived: sum of 3 quarters · filed 2023-02-28 | $222.32M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $53.06M 10-Q · filed 2022-05-10 | $103.49M derived: sum of 2 quarters · filed 2023-02-28 | $169.20M derived: sum of 3 quarters · filed 2023-02-28 | $177.13M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $50.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $116.14M derived: sum of 2 quarters · filed 2023-02-28 | $124.07M derived: sum of 3 quarters · filed 2023-02-28 | $128.03M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $65.70M 10-Q · filed 2021-11-05 | $73.64M derived: sum of 2 quarters · filed 2021-11-05 | $77.60M 10-Q · filed 2021-11-05 | $81.85M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $7.93M 10-Q · filed 2021-08-05 | $11.90M 10-Q · filed 2021-08-05 | $16.14M derived: sum of 3 quarters · filed 2022-03-01 | $18.77M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $3.96M 10-Q · filed 2021-05-10 | $8.21M derived: sum of 2 quarters · filed 2022-03-01 | $10.83M derived: sum of 3 quarters · filed 2022-03-01 | $15.46M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.87M derived: sum of 2 quarters · filed 2022-03-01 | $11.49M derived: sum of 3 quarters · filed 2022-03-01 | $17.05M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $2.62M 10-Q · filed 2020-11-10 | $7.25M derived: sum of 2 quarters · filed 2020-11-10 | $12.80M 10-Q · filed 2020-11-10 | $17.19M derived: sum of 4 quarters · filed 2020-11-10 | |
| 2019-06-30 | $4.62M 10-Q · filed 2020-08-10 | $10.18M 10-Q · filed 2020-08-10 | $14.56M derived: sum of 3 quarters · filed 2020-08-10 | $19.00M derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $5.56M 10-Q · filed 2020-05-11 | $9.94M derived: sum of 2 quarters · filed 2020-05-11 | $14.38M derived: sum of 3 quarters · filed 2020-05-11 | $18.63M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2018-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $8.82M derived: sum of 2 quarters · filed 2020-03-11 | $13.07M derived: sum of 3 quarters · filed 2020-03-11 | $18.31M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $4.43M 10-Q · filed 2019-11-07 | $8.68M derived: sum of 2 quarters · filed 2019-11-07 | $13.93M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $4.25M 10-Q · filed 2019-08-07 | $9.50M 10-Q · filed 2019-08-07 | |||
| 2018-03-31 | $5.25M 10-Q · filed 2019-05-02 | ||||
| 2017-12-31 | $18.31M 10-K · filed 2021-03-01 | $19.81M 10-K · filed 2018-03-14 | |||
| 2016-12-31 | $19.16M 10-K · filed 2019-03-18 | ||||
| 2015-12-31 | $13.43M 10-K · filed 2018-03-14 | ||||
| 2014-12-31 | $6.09M 10-K · filed 2017-02-27 | ||||
| 2013-12-31 | $2.48M 10-K · filed 2016-02-29 | ||||
| 2012-12-31 | $2.09M 10-K · filed 2014-03-12 | ||||
| 2011-12-31 | $2.05M 10-K · filed 2014-03-12 | ||||
| 2010-12-31 | $1.34M 10-K · filed 2013-03-12 | ||||
| 2009-12-31 | $1.53M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |